Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium.
Date
2019-02-01Author
Trabert, B
Poole, EM
White, E
Visvanathan, K
Adami, H-O
Anderson, GL
Brasky, TM
Brinton, LA
Fortner, RT
Gaudet, M
Hartge, P
Hoffman-Bolton, J
Jones, M
Lacey, JV
Larsson, SC
Mackenzie, GG
Schouten, LJ
Sandler, DP
O'Brien, K
Patel, AV
Peters, U
Prizment, A
Robien, K
Setiawan, VW
Swerdlow, A
van den Brandt, PA
Weiderpass, E
Wilkens, LR
Wolk, A
Wentzensen, N
Tworoger, SS
Ovarian Cancer Cohort Consortium (OC3),
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily and low-dose users. To prospectively investigate associations of analgesic use with ovarian cancer, we analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). METHODS: The current study included 758 829 women who at study enrollment self-reported analgesic use, among whom 3514 developed ovarian cancer. Using Cox regression, we assessed associations between frequent medication use and risk of ovarian cancer. Dose and duration were also evaluated. All statistical tests were two-sided. RESULTS: Women who used aspirin almost daily (≥6 days/wk) vs infrequent/nonuse experienced a 10% reduction in ovarian cancer risk (rate ratio [RR] = 0.90, 95% confidence interval [CI] = 0.82 to 1.00, P = .05). Frequent use (≥4 days/wk) of aspirin (RR = 0.95, 95% CI = 0.88 to 1.03), nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs; RR = 1.00, 95% CI = 0.90 to 1.11), or acetaminophen (RR = 1.05, 95% CI = 0.88 to 1.24) was not associated with risk. Daily acetaminophen use (RR = 1.28, 95% CI = 1.00 to 1.65, P = .05) was associated with elevated ovarian cancer risk. Risk estimates for frequent, long-term (10+ years) use of aspirin (RR = 1.15, 95% CI = 0.98 to 1.34) or nonaspirin NSAIDs (RR = 1.19, 95% CI = 0.84 to 1.68) were modestly elevated, although not statistically significantly so. CONCLUSIONS: This large, prospective analysis suggests that women who use aspirin daily have a slightly lower risk of developing ovarian cancer (∼10% lower than infrequent/nonuse)-similar to the risk reduction observed in case-control analyses. The observed potential elevated risks for 10+ years of frequent aspirin and NSAID use require further study but could be due to confounding by medical indications for use or variation in drug dosing.
Collections
Subject
Ovarian Cancer Cohort Consortium (OC3)
Humans
Ovarian Neoplasms
Aspirin
Analgesics
Anti-Inflammatory Agents, Non-Steroidal
Prognosis
Risk Assessment
Risk Factors
Follow-Up Studies
Prospective Studies
Middle Aged
United States
Europe
Female
Research team
Aetiological Epidemiology
Language
eng
Date accepted
2018-04-30
License start date
2019-02
Citation
Journal of the National Cancer Institute, 2019, 111 (2), pp. 137 - 145
Publisher
OXFORD UNIV PRESS INC
Related items
Showing items related by title, author, creator and subject.
-
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2,; Hollestelle, A; van der Baan, FH; Berchuck, A; Johnatty, SE; et al. (ACADEMIC PRESS INC ELSEVIER SCIENCE, 2016-05-01)OBJECTIVE: Clinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer ... -
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote, I; Banerjee, S; Gerdes, A-M; van Asperen, C; Marth, C; et al. (2016-12)Traditionally, BRCA genetic testing has been undertaken to identify patients and family members at future risk of developing cancer and patients have been referred for testing based on family history. However, the now ... -
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Morgan, RD; Clamp, AR; Barnes, BM; Timms, K; Schlecht, H; et al. (BMJ PUBLISHING GROUP, 2023-08-07)OBJECTIVE: Olaparib plus bevacizumab maintenance therapy improves survival outcomes in women with newly diagnosed, advanced, high-grade ovarian cancer with a deficiency in homologous recombination. We report data from the ...